YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
MORRISTOWN, N.J., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the Oppenheimer 26th Annual Healthcare Conference as follows:
| Date: | Tuesday, December 8, 2015 | ||||
| Time: | 2:10 p.m. EST | ||||
| Location: | The Westin New York Grand Central, NYC | ||||
The presentation will be webcast and available on the Investors section of the Company’s website at http://www.pernixtx.com/investors/webcasts-presentations/. A replay of the webcast will be available for 30 days after the date of the presentation.
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer [email protected] Lisa Wilson, 212-452-2793 In-Site Communications [email protected] Media Relations Marianne Lambertson, (800) 793-2145 ext. 1012 Vice President, Strategic Development [email protected]
